BlackRock’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,004,210
| Closed | -$4.78M | – | 5347 |
|
|
2024
Q1 | $4.78M | Sell |
3,004,210
-173,955
| -5% | -$277K | ﹤0.01% | 3630 |
|
|
2023
Q4 | $2.73M | Sell |
3,178,165
-661,714
| -17% | -$568K | ﹤0.01% | 3847 |
|
|
2023
Q3 | $4.11M | Sell |
3,839,879
-793,126
| -17% | -$849K | ﹤0.01% | 3672 |
|
|
2023
Q2 | $12M | Buy |
4,633,005
+526,863
| +13% | +$1.36M | ﹤0.01% | 3264 |
|
|
2023
Q1 | $16.8M | Sell |
4,106,142
-53,620
| -1% | -$219K | ﹤0.01% | 2997 |
|
|
2022
Q4 | $20.9M | Buy |
4,159,762
+93,185
| +2% | +$468K | ﹤0.01% | 2965 |
|
|
2022
Q3 | $53.2M | Buy |
4,066,577
+193,828
| +5% | +$2.54M | ﹤0.01% | 2368 |
|
|
2022
Q2 | $49.6M | Buy |
3,872,749
+1,033,075
| +36% | +$13.2M | ﹤0.01% | 2467 |
|
|
2022
Q1 | $43.3M | Buy |
2,839,674
+58,883
| +2% | +$898K | ﹤0.01% | 2626 |
|
|
2021
Q4 | $49.3M | Buy |
2,780,791
+335,959
| +14% | +$5.95M | ﹤0.01% | 2636 |
|
|
2021
Q3 | $51.4M | Buy |
2,444,832
+145,477
| +6% | +$3.06M | ﹤0.01% | 2615 |
|
|
2021
Q2 | $45.3M | Sell |
2,299,355
-465,225
| -17% | -$9.17M | ﹤0.01% | 2725 |
|
|
2021
Q1 | $80.4M | Buy |
2,764,580
+238,964
| +9% | +$6.95M | ﹤0.01% | 2291 |
|
|
2020
Q4 | $76.5M | Buy |
2,525,616
+81,177
| +3% | +$2.46M | ﹤0.01% | 2204 |
|
|
2020
Q3 | $38.9M | Buy |
2,444,439
+158,965
| +7% | +$2.53M | ﹤0.01% | 2390 |
|
|
2020
Q2 | $45.1M | Buy |
2,285,474
+33,968
| +2% | +$671K | ﹤0.01% | 2286 |
|
|
2020
Q1 | $27.8M | Sell |
2,251,506
-56,780
| -2% | -$700K | ﹤0.01% | 2402 |
|
|
2019
Q4 | $42.7M | Buy |
2,308,286
+1,653,937
| +253% | +$30.6M | ﹤0.01% | 2435 |
|
|
2019
Q3 | $9.06M | Buy |
654,349
+333,604
| +104% | +$4.62M | ﹤0.01% | 3219 |
|
|
2019
Q2 | $4.7M | Buy |
+320,745
| New | +$4.7M | ﹤0.01% | 3503 |
|